


Prescribing PANCREAZE to LifeLine Specialty Pharmacy

Prescribe PANCREAZE with confidence

LifeLine Specialty Pharmacy provides patients with **benefits investigation, prior authorization and appeals support as well as fulfillment with free shipping**. Determine the **PANCREAZE** dosing for your patient, write and send the prescription to LifeLine Specialty Pharmacy using one of the following:



Instructions to Fax

To	LifeLine Specialty Pharmacy
NCPDP	2141240
NPI	1568975464
FAX	833-785-4461

e-Prescribing via EMR

Select	LifeLine Specialty Pharmacy
NCPDP	2141240
NPI	1568975464

Rx CHECKLIST

- A patient's dose should be **individualized** based on age, weight, clinical symptoms, degree of steatorrhea and fat content of their diet.¹
- **Prescribe PANCREAZE for both meals and snacks** — usually, half of the prescribed dose for an individualized full meal should be given with each snack.¹

- ▶ LifeLine Specialty Pharmacy will contact your patient directly. Please provide the **LifeLine Specialty Pharmacy Patient Information Card** located at [HCP.PANCREAZE.com/materials](https://www.hcp.pancreaze.com/materials). Please note that LifeLine Specialty Pharmacy is **NOT AVAILABLE** to patients in California, Puerto Rico, Guam or the U.S. Virgin Islands.



Dosing questions? Review the **PANCREAZE Prescribing Information, online dosing calculator and PANCREAZE 37,000 unit dosing guide** at [HCP.PANCREAZE.com](https://www.hcp.pancreaze.com).


pancreaze[®]
(pancrelipase) DELAYED-RELEASE CAPSULES



With every meal and snack,
help them take control.

PANCREAZE... THE SYMPTOMS OF EPI.SM

Gerry, age 42
Celiac patient.
Diagnosed with EPI.
Actor portrayal



Choose **PANCREAZE** as your first-line enzyme replacement therapy

- Proven to improve EPI symptoms and fat and protein absorption.^{1,2}
- Available in 6 strengths — including a 37,000 unit dose.
- A trusted enzyme replacement therapy for over 10 years.

Important Safety Information

Fibrosing Colonopathy: Associated with high doses, usually over prolonged use and in pediatric patients with cystic fibrosis. Colonic stricture reported in pediatric patients less than 12 years of age with dosages exceeding 6,000 lipase units/kg/meal. Monitor during treatment for progression of preexisting disease. Do not exceed the recommended dosage, unless clinically indicated.

Hyperuricemia has been reported with high dosages; consider monitoring blood uric acid levels in patients with gout, renal impairment, or hyperuricemia.

Irritation of the oral mucosa may occur due to loss of protective enteric coating on the capsule contents.

The presence of porcine viruses that might infect humans cannot be definitely excluded.

Monitor patients with known reactions to proteins of porcine origin. If symptoms occur, initiate appropriate medical management; consider the risks and benefits of continued treatment.

References:

1. PANCREAZE Full Prescribing Information. Campbell, CA: VIVUS LLC; 2024. 2. Trapnell BC, et al. Efficacy and safety of PANCREAZE[®] for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. *J Cyst Fibros*. 2011;10(5):350-356.

Please read the accompanying **PANCREAZE Medication Guide** and **Full Prescribing Information**.

©2024 VIVUS LLC. All rights reserved.
500392.02-USP 12/2024

For more information visit: HCP.PANCREAZE.com



VIVUS